🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guilin
Clinical trial register · China

Clinical Trials in Guilin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University5 Sichuan Baili Pharmaceutical Co., Ltd.5 First Affiliated Hospital of Guangxi Medical University3 Guilin Medical University, China3 Institute of Medical Biology, Chinese Academy of Medical Sciences2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guilin

51 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Dongguan Shi, Guangzhou, Jiangmen, Zhongshan, Guilin
2026-09-30
Not yet open
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
NCT07791758Metastatic Colorectal Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-04
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155Systemic Lupus Erythematosus (SLE)
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Not yet open
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
NCT07764887Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
First Affiliated Hospital of Guangxi Medical University
Not applicable
536
Baise City, Beihai, Guigang, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2026-08-30
Not yet open
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2
48
Xiamen, Guangzhou, Guilin
2026-08-01
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Recruiting
CD38 Targeted -PET/ CT for Multiple Myeloma
NCT07782944Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Guilin Medical University, China
Not applicable
100
Guilin
2026-07-07
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Not yet open
Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)
NCT07469293Acute Ischemic Stroke
Southwest Hospital, China
Phase 3
488
Baise City, Guilin, Qiannan, Chengdu, Dali, Qujing, Ankang, Anyang
2026-03-25
Not yet open
Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants
NCT07045844Very Preterm Infant, Necrotizing Enterocolitis (NEC)
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
2,324
Guilin, Nanning, Yulin, Guizhou, Nanyang, Zhengzhou, Yiyang, Ganzhou
2026-03-02
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
NCT07375524Primary Sjögren Syndrome
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou
2026-03-01
Not yet open
Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control
NCT07330180Myopia, Myopia, Progressive
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
364
Chongqing, Foshan, Zhengzhou, Wuhan, Shenyang, Guilin, Xi’an
2026-01-01
Recruiting
Theranostic Applications of Radionuclides in Prostate Cancer
NCT07559201Prostate Cancer (Diagnosis)
Guilin Medical University, China
Not applicable
100
Guilin
2026-01-01
Recruiting
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
NCT07110415Coronary Heart Disease, Cardiac Dysfunction
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase 4
2,708
Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin
2025-11-06
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051Bronchiectasis
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)
Sun Yat-sen University
Phase 3
386
Guangzhou, Guilin, Sanya, Changsha, Nanjing
2025-08-15
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
NCT07105215Solid Tumors
RemeGen Co., Ltd.
Phase 1/2
312
Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang
2025-08-11
By invitation
Study on the Persistence of Immunity Following EV71 Vaccination
NCT07144202Hand, Foot, and Mouth Disease, Hand, Foot, and Mouth Disease (HFMD)
Institute of Medical Biology, Chinese Academy of Medical Sciences
Observational
270
Guilin
2025-08-10
Recruiting
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
NCT07133516Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, Cardiovascular Diseases (CVD), Echocardiography
First Hospital of China Medical University
Observational
1,600
Huainan, Fuzhou, Meizhou, Shantou, Shenzhen, Baise City, Guilin, Liuzhou
2025-07-22
Recruiting
An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes
NCT06959030Type 2 Diabetes Mellitus (T2DM)
Second Affiliated Hospital of Guangxi Medical University
Observational
10,000
Beihai, Guilin, Nanning, Qingdao
2025-06-19
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NCT06756451Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Not yet open
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979Obesity
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
408
Hefei, Xuancheng, Chongqing, Fuzhou, Lanzhou, Guilin, Liuzhou, Nanning
2025-03
Not yet open
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
NCT06800950Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 3
4,400
Guilin, Nanning
2025-02-08
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039Diffuse Large B-Cell Lymphoma
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
NCT07141056HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
Guilin Medical University, China
Observational
700
Zhanjiang, Guilin, Shaoyang
2025-01-01
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Recruiting
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
NCT06492460Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
NCT06241781Adult
Grit Biotechnology
Phase 2
83
Beijing, Fuzhou, Shenzhen, Guilin, Ha’erbin, Luoyang, Zhengzhou, Wuhan
2024-04-02
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
NCT06145893Behçet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
NCT05892354Locally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Not applicable
190
Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2023-06-12
Active, closed
CRUSTAL Study in China
NCT05828186Coronary Artery Disease, Calcification
First Affiliated Hospital of Guangxi Medical University
Observational
200
Liuzhou, Yulin, Nanjing, Guilin, Guiping
2023-05-04
Active, closed
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Recruiting
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
NCT05717790Nasopharyngeal Carcinoma by AJCC V8 Stage
Fourth Affiliated Hospital of Guangxi Medical University
Not applicable
288
Baise City, Guilin, Liuzhou, Nanjing, Qinzhou, Wuzhou
2022-12-01
Recruiting
Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05527470Nasopharyngeal Carcinoma
Wei Jiang
Phase 3
440
Guilin, Wuzhou
2022-11-11
Active, closed
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
NCT05339685Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257Limited-Stage Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Active, closed
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Active, closed
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
NCT05054439Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Active, closed
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
NCT05020457Non Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Recruiting
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
NCT07392736Solid Tumor
Advenchen Laboratories, LLC
Phase 1/2
228
Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning
2021-10-26
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
Recruiting
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
NCT06524427Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Active, closed
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
NCT03998254Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
6,000
Guilin, Changzhi, Yuncheng, Mianyang
2019-06-26
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guilin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in Guilin.

How many clinical trials are recruiting in Guilin?

25 of the 51 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 13 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guilin), 51 studies
PhaseStudiesRecruitingShare
Phase 315529.4%
Phase 213725.5%
Not applicable8515.7%
Observational6311.8%
Phase 1/2437.8%
Phase 1213.9%
Phase 2/3203.9%
Phase 4112%

Most active sponsors

Lead sponsors with the most studies (Guilin)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.50
Sun Yat-sen University54
First Affiliated Hospital of Guangxi Medical University31
Guilin Medical University, China33
Amgen20
Institute of Medical Biology, Chinese Academy of Medical Sciences20
Nanjing Leads Biolabs Co.,Ltd21
Pfizer21
Shanghai Escugen Biotechnology Co., Ltd20
Abbisko Therapeutics Co, Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.